Chuke Nwachuku

St. Luke's University Health Network — United States

Medicine · Health Sciences

13h-index2.0kcitations25works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Blood Pressure and Hypertension Studies(11), Hemoglobinopathies and Related Disorders(4), Health Systems, Economic Evaluations, Quality of Life(4), Myeloproliferative Neoplasms: Diagnosis and Treatment(4), Pharmaceutical Practices and Patient Outcomes(3)

Publications25 total

RETHINKING THE 10% RULE: PATIENT-SPECIFIC MODELLING OF STRAIN IN DISTAL FEMUR FRACTURES
Orthopaedic Proceedings·2023
Effect of Caffeinated Coffee Consumption on Renal Function in Health and Diabetes: A Double-Edged Sword
Archives of Nephrology·2020Open Access
A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease
UNC Libraries·2019· 1 citedOpen Access
Edoxaban Plus Aspirin vs Dual Antiplatelet Therapy in Endovascular Treatment of Patients With Peripheral Artery Disease: Results of the ePAD Trial
Journal of Endovascular Therapy·2018· 95 citedOpen Access
A Review of Antithrombotic Therapy and the Rationale and Design of the Randomized Edoxaban in Patients With Peripheral Artery Disease (ePAD) Trial Adding Edoxaban or Clopidogrel to Aspirin After Femoropopliteal Endovascular Intervention
Journal of Endovascular Therapy·2015· 19 cited
A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease
Journal of Hematology & Oncology·2013· 70 citedOpen Access
Rationale and design of the TAXUS Libertē Post-Approval Study: Examination of patients receiving the TAXUS Liberté stent with concomitant prasugrel therapy in routine interventional cardiology practice
American Heart Journal·2012· 4 cited
Biomarkers of Hemostatic Activation in a Randomized, Double-Blind, Phase 2 Study of Prasugrel Compared to Placebo in Adults with Sickle Cell Disease
Blood·2011
A Randomized, Double-Blind, Adaptive Phase 2 Multi-Center Study of Prasugrel Compared to Placebo in Adults with Sickle Cell Disease
Blood·2011· 2 cited
Management of High Blood Pressure in Clinical Practice: Perceptible Qualitative Differences in Approaches Utilized by Clinicians
Journal of Clinical Hypertension·2008· 7 citedOpen Access
Metabolic and Clinical Outcomes in Nondiabetic Individuals With the Metabolic Syndrome Assigned to Chlorthalidone, Amlodipine, or Lisinopril as Initial Treatment for Hypertension
Diabetes Care·2008· 116 citedOpen Access
Cost-effectiveness of Chlorthalidone, Amlodipine, and Lisinopril as First-step Treatment for Patients with Hypertension: An Analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Journal of General Internal Medicine·2008· 37 citedOpen Access
Health-Related Quality of Life and Cost-Effectiveness Components of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Rationale and Design
The American Journal of Cardiology·2007· 29 citedOpen Access
The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) heart failure Validation Study: Diagnosis and prognosis
American Heart Journal·2006· 69 cited
Incidence and Predictors of Angioedema in Elderly Hypertensive Patients at High Risk for Cardiovascular Disease: A Report From the Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Journal of Clinical Hypertension·2006· 52 citedOpen Access
Clinical Events in High-Risk Hypertensive Patients Randomly Assigned to Calcium Channel Blocker Versus Angiotensin-Converting Enzyme Inhibitor in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
Hypertension·2006· 169 cited
Re: Hawkins RG, Houston MC Is population-wide diuretic use directly associated with the incidence of end-stage renal disease in the United States? A hypothesis. Am J Hypertens. 2005 Jun;18(6):744-9
American Journal of Hypertension·2006· 6 cited
Outcomes in high risk hypertensives randomized to CCB vs ACE inhibitor in ALLHAT
American Journal of Hypertension·2005· 1 cited
Angioedema in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
American Journal of Hypertension·2005· 4 cited
Characteristics and Lipid Distribution of a Large, High‐Risk, Hypertensive Population: The Lipid‐Lowering Component of the Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Journal of Clinical Hypertension·2003· 15 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Barry R. Davis(9), Henry R. Black(7), Linda B. Piller(6), William C. Cushman(5), Charles E. Ford(5), Kenneth J. Winters(5), Jeffrey A. Cutler(4), Jeffrey L. Probstfield(4), Sara Pressel(4), Ted Wun(4), Lori E. Heath(4), Joseph A. Jakubowski(4), Jackson T. Wright(3), Lara M. Simpson(3), Paul K. Whelton(3), Denis Soulières(3), Lakshmanan Krishnamurti(3), Abdullah Kutlar(3), Kenneth I. Ataga(3), Charles Knupp(3)